Edgewise Therapeutics (EWTX) Other Accumulated Expenses (2020 - 2026)

Edgewise Therapeutics has disclosed Other Accumulated Expenses across 7 years of filings, most recently posting $1.2 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $1.2 million, up 14.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 14.34% YoY), and the FY2025 annual result was $759000.0, up 2.43% from the prior year.
• Other Accumulated Expenses came in at $1.2 million for Q1 2026 at Edgewise Therapeutics, up from $759000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.2 million in Q1 2026 to a low of $399000.0 in Q4 2023.
• The 5-year median for Other Accumulated Expenses is $804000.0 (2022), against an average of $830529.4.
• Across the five-year window, Other Accumulated Expenses jumped 235.77% in 2022 and plunged 62.29% in 2023, its largest moves.
• Edgewise Therapeutics' Other Accumulated Expenses stood at $1.1 million in 2022, then tumbled by 62.29% to $399000.0 in 2023, then surged by 85.71% to $741000.0 in 2024, then advanced by 2.43% to $759000.0 in 2025, then soared by 56.52% to $1.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.2 million (Q1 2026), $759000.0 (Q4 2025), and $714000.0 (Q3 2025), per Business Quant data.